You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Harvard Business School
AstraZeneca
McKesson
Mallinckrodt
Express Scripts
Medtronic

Last Updated: April 2, 2020

DrugPatentWatch Database Preview

Aztreonam - Generic Drug Details

» See Plans and Pricing

« Back to Dashboard

What are the generic drug sources for aztreonam and what is the scope of patent protection?

Aztreonam is the generic ingredient in four branded drugs marketed by Gilead, Bristol Myers Squibb, Fresenius Kabi Usa, and West-ward Pharms Int, and is included in five NDAs. There are four patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Aztreonam has fifty-six patent family members in twenty-one countries.

There are eight drug master file entries for aztreonam. Three suppliers are listed for this compound.

Drug Prices for aztreonam

See drug prices for aztreonam

Recent Clinical Trials for aztreonam

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
National Institute of Allergy and Infectious Diseases (NIAID)Phase 1
University of WashingtonPhase 2/Phase 3
Hospital Universitari Joan XXIII de Tarragona.Phase 2/Phase 3

See all aztreonam clinical trials

Pharmacology for aztreonam
Medical Subject Heading (MeSH) Categories for aztreonam
Synonyms for aztreonam
(2S,3S)-3-({(2Z)-2-(2-ammonio-1,3-thiazol-4-yl)-2-[(1-carboxy-1-methylethoxy)imino]ethanoyl}amino)-2-methyl-4-oxoazetidine-1-sulfonate
(2S,3S)-3-({(2Z)-2-(2-ammonio-1,3-thiazol-4-yl)-2-[(1-carboxy-1-methylethoxy)imino]ethanoyl}amino)-2-methyl-4-oxoazetidine-1-sulfonate(aztreonam)
(3S)-2-Oxo-3beta-[2-(2-aminothiazole-4-yl)-2-(1-carboxy-1-methylethoxyimino)acetylamino]-4alpha-methylazetidine-1-sulfonic acid
(E)-2-((((2-Amino-4-thiazolyl)(((2S,3S)-2-methyl-4-oxo-1-sulfo-3-azetidinyl)carbamoyl(methylene)amino(oxy)-2-methylpropionic acid
(Z)-2-[[[(2-Amino-4-thiazolyl)[[(2S,3S)-2-methyl-4-oxo-1-sulfo-3- azetidinyl]carbamoyl]methylene]amino]oxy]-2-methylpropionic acid
[2S-[2alpha,3beta(Z)]]-2-[[[1-(2-Amino-4-thiazolyl)-2-[(2-methyl-4-oxo-1-sulfo-3-azetidinyl)amino]-2-oxoethylidene]amino]oxy]-2-methylpropanoic acid
110A380
149496-40-2
2-((((E)-1-(2-aminothiazol-4-yl)-2-(((2S,3S)-2-methyl-4-oxo-1-sulfoazetidin-3-yl)amino)-2-oxoethylidene)amino)oxy)-2-methylpropanoic acid
2-((((Z)-1-(2-aminothiazol-4-yl)-2-(((2S,3S)-2-methyl-4-oxo-1-sulfoazetidin-3-yl)amino)-2-oxoethylidene)amino)oxy)-2-methylpropanoic acid
2-({[(1E)-1-(2-amino-1,3-thiazol-4-yl)-2-{[(2S,3S)-2-methyl-4-oxo-1-sulfoazetidin-3-yl]amino}-2-oxoethylidene]amino}oxy)-2-methylpropanoic acid
2-({[(1Z)-1-(2-amino-1,3-thiazol-4-yl)-2-{[(2S,3S)-2-methyl-4-oxo-1-sulfoazetidin-3-yl]amino}-2-oxoethylidene]amino}oxy)-2-methylpropanoic acid
2-[(Z)-[1-(2-aminothiazol-4-yl)-2-[[(2S,3S)-2-methyl-4-oxo-1-sulfo-azetidin-3-yl]amino]-2-oxo-ethylidene]amino]oxy-2-methyl-propanoic acid
2-[[(2-amino-1,3-thiazol-4-yl)-[[(2S,3S)-2-methyl-4-oxo-1-sulfo-azetidin-3-yl]carbamoyl]methylidene]amino]oxy-2-methylpropanoic acid
2-[[(Z)-[1-(2-Amino-4-thiazolyl)-2-[[(2S,3S)-2-methyl-4-oxo-1-sulfo-3-azetidinyl]amino]-2-oxoethylidene]amino]oxy]-2-methylpropionic Acid
2-[1-(2-Amino-thiazol-4-yl)-1-((2S,3S)-2-methyl-4-oxo-1-sulfo-azetidin-3-ylcarbamoyl)-meth-(Z)-ylideneaminooxy]-2-methyl-propionic acid
5Q55M3D9UA
78110-38-0
99341-02-3
A-9950
AB01563305_01
AB2000129
ABP000466
AC-4330
AKOS015840157
AKOS015961777
AKOS015969724
AKOS034796899
API0001576
AS-13760
Azactam
Azetreonam
Azthreonam
Aztreonam (Azactam, Cayston)
Aztreonam, analytical standard
Aztreonam, Antibiotic for Culture Media Use Only
Aztreonam, Pharmaceutical Secondary Standard; Certified Reference Material
Aztreonam, United States Pharmacopeia (USP) Reference Standard
Aztreonam(Azactam, Cayston)/
Aztreonam(Azactam)
BCP9000372
BCPP000356
BDBM50240480
BIDD:GT0765
BPBio1_000121
BRD-K36547807-001-02-4
BRD-K62607865-001-03-0
BSPBio_000109
BSPBio_002512
CA0151
CAS-78110-38-0
CC-24234
CCG-213342
CCG-220185
CHEBI:161680
CHEBI:94511
CHEMBL158
CHEMBL410081
CS-1902
DTXSID20244045
E-Aztreonam
G2B4VE5GH8
HMS1568F11
HMS2090K09
HMS2095F11
HMS3712F11
HY-B0129
J10266
MFCD00072145
MLS003915628
MLS006011974
Monobactam;SQ 26776;Squibb 26776;Azactam;Cayston
NCGC00016936-01
NCGC00016936-02
NCGC00179656-01
NSC-646279
NSC-758913
NSC646279
NSC758913
Pharmakon1600-01505122
Prestwick_914
Prestwick2_000185
Prestwick3_000185
Primbactam
Propanoic acid, 2-(((1-(2-amino-4-thiazolyl)-2-((2-methyl-4-oxo-1-sulfo-3-azetidinyl)amino)-2-oxoethylidene)amino)oxy)-2-methyl-, (2S-(2alpha,3beta(E)))-
Propanoic acid, 2-(((E)-(1-(2-amino-4-thiazolyl)-2-(((2S,3S)-2-methyl-4-oxo-1-sulfo-3-azetidinyl)amino)-2-oxoethylidene)amino)oxy)-2-methyl-
Propanoic acid, 2-[[(Z)-[1-(2-amino-4-thiazolyl)-2-[[(2S,3S)-2-methyl-4-oxo-1-sulfo-3-azetidinyl]amino]-2-oxoethylidene]amino]oxy]-2-methyl-
PubChem13620
Q27262730
Q418546
rel-Aztreonam
S1505
SBI-0206775.P001
SCHEMBL13616074
SCHEMBL37512
SMR002204030
SMR004703537
SO-26776
SPECTRUM1505122
SQ 26776
SQ 28429
SQ-26776
SQ-28429
Squibb 26776
SR-01000841814
SR-01000841814-2
SR-01000841814-3
STL011049
UNII-5Q55M3D9UA
UNII-G2B4VE5GH8
WZPBZJONDBGPKJ-VEHQQRBSSA-N
ZINC12503091
ZINC3830264

US Patents and Regulatory Information for aztreonam

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bristol Myers Squibb AZACTAM aztreonam INJECTABLE;INJECTION 050580-002 Dec 31, 1986 AP RX Yes Yes   Start Trial   Start Trial   Start Trial
West-ward Pharms Int AZTREONAM aztreonam INJECTABLE;INJECTION 065286-001 Mar 23, 2011 DISCN No No   Start Trial   Start Trial   Start Trial
Fresenius Kabi Usa AZTREONAM aztreonam INJECTABLE;INJECTION 065439-003 Jun 18, 2010 AP RX No No   Start Trial   Start Trial   Start Trial
Gilead CAYSTON aztreonam FOR SOLUTION;INHALATION 050814-001 Feb 22, 2010 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Bristol Myers Squibb AZACTAM aztreonam INJECTABLE;INJECTION 050580-001 Dec 31, 1986 DISCN No No   Start Trial   Start Trial   Start Trial
Fresenius Kabi Usa AZTREONAM aztreonam INJECTABLE;INJECTION 065439-002 Jun 18, 2010 AP RX No No   Start Trial   Start Trial   Start Trial
Bristol Myers Squibb AZACTAM aztreonam INJECTABLE;INJECTION 050580-003 Dec 31, 1986 AP RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for aztreonam

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1353647 11C0030 France   Start Trial PRODUCT NAME: AZTREONAM LYSINE; REGISTRATION NO/DATE IN FRANCE: EU/1/09/543/001 DU 20090921; REGISTRATION NO/DATE AT EEC: EU/1/09/543/001 DU 20090921
2158901 122018000042 Germany   Start Trial PRODUCT NAME: AZTREONAMLYSIN; REGISTRATION NO/DATE: EU/1/09/543/001 20090921
1353647 2011C/029 Belgium   Start Trial PRODUCT NAME: AZTREONAM LYSINE; AUTHORISATION NUMBER AND DATE: EU/1/09/543/001 20090923
1353647 C300492 Netherlands   Start Trial PRODUCT NAME: AZTREONAM, NIET IN EEN SAMENSTELLING MET ARGININE, OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT VAN AZTREONAM, ANDERS DAN EEN ARGININEZOUT, IN HET BIJZONDER ALS AZTREONAMLYSINE; REGISTRATION NO/DATE: EU/1/09/543/001 20090921
1353647 C01353647/01 Switzerland   Start Trial PRODUCT NAME: AZTREONAMLYSIN; REGISTRATION NO/DATE: SWISSMEDIC 59389 06.12.2010
1353647 27/2011 Austria   Start Trial PRODUCT NAME: AZTREONAMLYSIN; REGISTRATION NO/DATE: EU/1/09/543/001 20090921
1353647 1190027-1 Sweden   Start Trial MARKETING AUTHORIZATION NUMBER AND DATE OF GRANT/NOTIFICATION: EU/1/09/543/001, 2009-09-23; PERIOD OF VALIDITY (FROM - UNTIL): 2021-12-21 - 2024-09- 22
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
AstraZeneca
McKesson
Mallinckrodt
Express Scripts
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.